Papers
5
Total Citations
243
H-Index
5
About
Rosa Mejia is a urological oncology researcher whose work has significantly advanced the surgical and diagnostic management of prostate cancer. Her research focuses on robot-assisted surgical techniques, pelvic lymphadenectomy, and biomarker-based risk stratification — areas where her contributions have meaningfully shaped clinical practice. Mejia's most impactful work centers on optimizing robot-assisted radical prostatectomy (RARP) and lymph node dissection. Her 2013 standardized comparison of limited versus extended pelvic lymphadenectomy (80 citations) provided critical evidence supporting extended dissection for improved staging and therapeutic benefit, directly informing European Association of Urology guidelines. Her investigation into salvage RARP (74 citations) offered one of the field's clearest single-institution analyses of outcomes in this technically demanding procedure, guiding surgeons managing patients with recurrent disease. Her 2012 study on robotic extended lymphadenectomy for intermediate- and high-risk prostate cancer (61 citations) further cemented the oncological rationale for this approach. Beyond surgical technique, Mejia has explored precision diagnostics, examining how expressed prostatic secretion biomarkers and two-stage classifier models incorporating PCA3 and PSA proteolytic activity can refine active surveillance candidacy and predict biochemical recurrence. Her body of work reflects a commitment to improving both surgical precision and personalized risk assessment for prostate cancer patients.
Research Focus
Key Achievements
Top Papers
- 1
- 2
- 3
- 4
- 5